Anthem Biosciences Limited — Investor Meet, 22-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Anthem Biosciences delivered a strong FY26 with consolidated revenue up 18% to Rs. 2,280 Cr and PAT growing 31% to Rs. 592 Cr. Q4 was a record quarter, seeing revenue climb 26% and PAT soar 130% YoY, boosted by backward integration. Management aims for ~20% growth and high profitability, noting destocking impacts are largely behind. Significant capacity expansion includes Unit 4, a Rs. 1,200 Cr investment expected to double custom synthesis capacity by FY28. The company actively seeks acquisitions, focusing on advanced technologies (peptides, ADCs, oligos) and early-stage projects, building sticky client relationships. Outlook is confident for sustained market leadership.